Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAVERA: Elacestrant and Everolimus in ER+ Endometrial Cancer
NCT07634601Phase 2Not yet recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in endometrial cancer (EC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
elacestrant
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07634601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634601.